OncoSec Announces Key Corporate Initiatives at Inaugural Investor & Analyst Day on November 17, 2016

SAN DIEGO, Nov. 17, 2016 /PRNewswire/ -- OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, will provide updates today on multiple key corporate initiatives at the Company's inaugural Investor and Analyst Day in San Diego, CA, including plans for a melanoma combination directed-registration study of OncoSec's lead product candidate, ImmunoPulse® IL-12, in combination with  anti-PD-1 therapy.  In addition, the Company will provide details on its preclinical multi-gene plasmid constructs, Tissue-based Real-time Adaptive Controlled Electroporation (TRACE™), and its Technology Access Program (TAP). OncoSec will also highlight the new Phase II melanoma data that was recently presented at the Society for Immunotherapy of Cancer Annual Meeting ("SITC 2016").

"By focusing our clinical programs on patients who do not respond to anti-PD-1 therapy, we are committed to developing therapies for those in critical need of alternative treatments," said Punit Dhillon, President and CEO of OncoSec. "The favorable anti-tumor activity and safety data garnered from the Investigator Sponsored Trial (IST) Phase II clinical trial combining ImmunoPulse® IL-12 and KEYTRUDA^® (pembrolizumab) provides us with additional confidence to move forward with key regulatory, clinical and commercial efforts aimed at achieving marketing approval for ImmunoPulse^® IL-12 in anti-PD-1 non responder advanced melanoma.  We are pleased to be focused on a registration-directed clinical program with a regulatory path that we hope will lead to a potential FDA approval for our first commercial product in 2019."

"We are changing the way clinicians and scientists think about the use of technology to manipulate cellular activity with the power of DNA construct delivery and activation through our innovative, easy to use, next-generation gene electro-transfer devices," continued Mr. Dhillon.  "We believe our development strategy for ImmunoPulse^® IL-12 will lead to a large market opportunity, and can generate significant value for shareholders and provide a strong foundation for advancing OncoSec's next clinical candidate in first-in-human studies in 2018."

A replay of the event webcast will be available shortly after the meeting and can be accessed for up to 12 months through the Events and Presentations section under the Investors tab of OncoSec's website at www.oncosec.com.

About OncoSec Medical Incorporated
OncoSec is a biotechnology company developing DNA-based intratumoral immunotherapies with an investigational technology, ImmunoPulse^®, for the treatment of cancer.  ImmunoPulse^® is designed to enhance the local delivery and uptake of DNA-based immune-targeting agents, such as IL-12. In Phase I and II clinical trials, ImmunoPulse^®IL-12 has demonstrated a favorable safety profile and evidence of anti-tumor activity in the treatment of various solid tumors as well as the potential to initiate a systemic immune response. OncoSec's lead program, ImmunoPulse^®IL-12, is currently in clinical development for several indications, including metastatic melanoma, head and neck cancer, and triple-negative breast cancer. The program's current focus is on the significant unmet medical need in patients with melanoma who are refractory or non-responsive to anti-PD-1/PD-L1 therapies. In addition to ImmunoPulse^® IL-12, the Company is also identifying and developing new immune-targeting agents for use with the ImmunoPulse^® platform. For more information, please visit www.oncosec.com.

OncoSec Medical Incorporated, Forward Looking Statements
To the extent statements contained in this press release are not descriptions of historical facts regarding OncoSec Medical Incorporated, they may be considered forward looking statements, as described in the Private Securities Litigation Reform Act of 1995, reflecting management's current beliefs and expectations. Forward looking statements speak only as of the date they are made, and they are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry's actual results, levels of activity, performance or achievements to be materially different from those anticipated by such statements. You can identify forward-looking statements by words such as "aimed at," "anticipate," "believe," "can," "could," "estimate," "expect," "focus," "intend," "may," "plan," "potential," "predict," "project," "should," "will," "would," or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes. Forward looking statements contained in this press release include, but are not limited to, statements regarding: (i) the success and timing of our product development activities and clinical trials; (ii) our ability to develop and commercialize our product candidates; (iii) our plans to research, discover, evaluate and develop additional potential product, technology and business candidates and opportunities; (iv) our and our partners' ability to develop, manufacture and commercialize our product candidates and to improve the manufacturing process; (v) the size and growth potential of the markets for our product candidates, and our ability to serve those markets; (vi) the rate and degree of acceptance of our product candidates; (vii) our ability to attract and retain key scientific or management personnel; (viii) the anticipated timing of clinical data availability; (ix) the anticipated timing of commercial launch of ImmunoPulse^® IL-12; (x) our ability to meet our milestones; (xi) our expectations regarding our ability to obtain and maintain intellectual property protection; (xii) the level of our corporate expenditures; (xiii) the assessment of our technology by potential corporate partners; and, (xiv) the impact of capital market conditions on our Company. Undue reliance should not be placed on forward looking statements. Such statements are subject to factors, risks and uncertainties, such as those described in our periodic filings with the Securities and Exchange Commission, including without limitation our Quarterly Reports on Form 10-Q, our annual reports on Form 10-K and other filings. Various factors may cause actual results to differ materially from those expressed or implied by such forward looking statements. We undertake no obligation to publicly update any forward-looking statements. OncoSec's investigational drug and device products have not been approved or cleared by the FDA.

CONTACT:
Sophia Ononye, PhD MPH MBA
Associate Director, Investor Relations and Corporate Communications
OncoSec Medical Incorporated
855-662-6732
[email protected]

Logo - http://photos.prnewswire.com/prnh/20120905/LA68078LOGO

SOURCE OncoSec Medical Incorporated

Related Links

http://www.oncosec.com